Natural Products as Sources of New Drugs over the 30 Years from 1981 to 2010
By D. Newman, G. Cragg. Journal of Natural Products, 2012
4,981 citations recorded by the source corpus.
This review is an updated and expanded version of the three prior reviews that were published in this journal in 1997, 2003 and 2007. In the case of all approved therapeutic agents, the time frame has been extended to cover the 30 years from January 1st 1981 to December 31st 2010 for all diseases world-wide, and from 1950 (earliest so far identified) to December 2010 for all approved antitumor drugs world-wide. We have continued to utilize our secondary subdivision of a “natural product mimic” or “NM” to join the original primary divisions, and have added a new designation “natural product botanical” or “NB” to cover those botanical “defined mixtures” that have now been recognized as drug entities by the FDA and similar organizations. From the data presented, the utility of natural products as sources of novel structures, but not necessarily the final drug entity, is still alive and well. Thus, in the area of cancer, over the time frame from around the 1940s to date, of the 175 small molecules, 131 or 74.8% are other than “S” (synthetic), with 85 or 48.6% actually being either natural products or directly derived there from. In other areas, the influence of natural product structures is quite marked with, as expected from prior information, the anti-infective area being dependent on natural products and their structures. Although combinatorial chemistry techniques have succeeded as methods of optimizing structures, and have been used very successfully in the optimization of many recently approved agents, we are only able to identify only one de novo combinatorial compound approved as a drug in this 30-year time frame. We wish to draw the attention of readers to the rapidly evolving recognition that a significant number of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the “host from whence it was isolated”, and therefore we consider that this area of natural product research should be expanded significantly.
Subfields: Biotechnology, Organic Chemistry, Pharmacology
View Paper: https://www.semanticscholar.org/paper/d92967b71e44bf68161e01688712f562c80eb386
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biotechnology
In Organic Chemistry
In Pharmacology
- Tilmann Weber
- Marnix H. Medema
- Michael A. Fischbach
- Kai Blin
- G. Cragg
- D. Newman
- Eriko Takano
- Leonard Katz
Citations in the corpus
- Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies (2022, background): “Ongoing research and development into natural products result in nearly 50% of currently available cancer treatments being derived directly or indirectly from natural ingredients [151,152].”
- PRISM 3: expanded prediction of natural product chemical structures from microbial genomes (2017, background): “Microbial secondary metabolism has historically represented a rich resource of evolved, bioactive small molecules, which form the foundations of many therapeutic regimens (1).”
- antiSMASH 2.0—a versatile platform for genome mining of secondary metabolite producers (2013, background): “Many microorganisms produce secondary metabolites with interesting bioactivities, including antibiotics, anti-cancer agents and many other drugs (1).”
- Discovery and resupply of pharmacologically active plant-derived natural products: A review (2015, background): “Of the 1073 new chemical entities belonging to the group of small molecules that had been approved between 1981 and 2010, only 36% were purely synthetic, while more than the half were derived or inspired from nature (Newman and Cragg, 2012).”
- Metabolites from marine invertebrates and their symbiotic microorganisms: molecular diversity discovery, mining, and application (2019, background): “2010; Newman and Cragg 2016b).”
- Sweet cherry: Composition, postharvest preservation, processing and trends for its future use (2016, background): “Most of the current therapies, especially for treatment of cancer have been derived from natural resources (Newman & Cragg, 2012), therefore further purification of individual compounds which are rich in the sweet cherries should be encouraged to prepare materials for utilisation in the health and…”